At a glance
ClinicalIndex Comparison RecordPhase 1Not Yet Recruiting· 20 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Skin Ulcer
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 15, 2021·Updated Apr 17, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Skin Ulcer. Not yet recruiting, targeting 20 participants across 1 site.
Detailed Summary
This trial will study the safety and efficacy of intravenous infusion and intralesional injection of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Skin Ulcer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Ulcer
CountriesAntigua and Barbuda
Collaborators--
Timeline
Phase 1Not Yet Recruiting
20222023202420252026202720282029
First PostedDec 2021
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionDec 2028
First PostedDec 15, 2021
Enrollment StartDec 1, 2025
Primary CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 4.5 years agoPrimary completion in 2.4 years
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells